TP53 and acute myeloid leukemia: The combination of APR-246 with azacitidine has shown early promising activity in TP53-mutant MDS and AML with CR/CRi rates of 75–87%, and is being tested in an international phase 3 randomized placebo-controlled trial (NCT03745716) (58, 59).